Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy
A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects With Immunoglobulin A Nephropathy (IgAN)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older at the time of screening
- Participant may be of any race or ethnicity
- Participant must have a biopsy-proven diagnosis of IgAN.
- Participant's blood pressure is ≤130/80 mmHg at Screening
- Participant is on maximally tolerated dose of an angiotensin-converting enzyme (ACE) inhibitor and/or angiotensin receptor blocker (ARB) for at least 3 months prior to the baseline visit.
- Participant must present at screening with current proteinuria levels between 1 g/24 h and 3.5 g/24 h, based on spot urine protein-to-creatinine ratio (UPCR)
- Participant must present at screening with an estimated glomerular filtration rate (eGFR) >40mL/min/1.73m^2
- If a female of childbearing potential, participant must have a negative pregnancy test at screening, is not currently breastfeeding, and agrees to employ adequate birth control measures for the duration of the study. Male participants with female partners of childbearing potential must agree to use adequate birth control measures for the duration of the study
- Participant is willing and able to comply with the requirements of this protocol and agrees to sign an informed consent form prior to any study-related activities
Exclusion Criteria:
- Participant has a history or current evidence of renal disease other than IgAN
- Participants with evidence of rapidly progressive disease
- Participant has IgAN with histologic evidence of advanced tubular atrophy and interstitial
- History or current evidence of other autoimmune disease
- History or current evidence of any chronic or uncontrolled medical condition which could, in the opinion of the Investigator, affect the participant's safety and ability to adhere to this protocol
- History or current evidence of a severe acute or chronic infection
- Use of systemic corticosteroids within 3 months prior to baseline, or anticipated use during the treatment period (Week 1 through Week 4). Note: Corticosteroids administered by inhalation or intranasally, or limited topical use of low-potency topical corticosteroids are allowed throughout the study.
- Known hypersensitivity or allergic reaction to any E. coli-derived recombinant product, yeast extract, or to the IP or any of its excipients
- Treatment with any immunomodulatory/immunosuppressive compound or monoclonal antibody for any indication within 6 months (unless otherwise stated) prior to screening (eg, B cell-depleting agents [eg, rituximab, epratuzumab] for ≥48 weeks; B-cell modifying agents [eg, belimumab, atacicept] for ≥24 weeks; IV immunoglobulins for ≥12 weeks and all other immunosuppressive treatments [eg, methotrexate, cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine] for ≥12 weeks)
- Clinically significant laboratory abnormalities prior to baseline
- History of any malignancy within past 5 years prior to screening (except for basal and squamous cell carcinomas of the skin, in situ cervical cancer, and stable prostate cancer that does not require treatment)
- History of tonsillectomy within 2 months prior to screening
- Participation in another clinical study involving an IP or investigational device within 30 days prior to screening or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
- Participant is a family member or employee of the Investigator
- A female participant who is pregnant or nursing at the time of screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SM101 12 mg/kg
Human soluble recombinant Fcγ Receptor IIB
|
Human soluble recombinant Fcγ Receptor IIB
Other Names:
|
|
Experimental: SM101 24 mg/kg
Human soluble recombinant Fcγ Receptor IIB
|
Human soluble recombinant Fcγ Receptor IIB
Other Names:
|
|
Placebo Comparator: Placebo
L-histidine-buffered saline with mannitol, sucrose, and polysorbate 2
|
L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent change in proteinuria from Baseline to Week 24
Time Frame: Baseline and Week 24
|
Baseline and Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants who demonstrate a ≥30% reduction from Baseline in proteinuria
Time Frame: Baseline, Week 8, Week 12, Week 18, and Week 24
|
Baseline, Week 8, Week 12, Week 18, and Week 24
|
|
|
Number of participants who reach and maintain proteinuria levels below 1.0 g/24 h
Time Frame: Week 8, Week 12, Week 18, and Week 24
|
Week 8, Week 12, Week 18, and Week 24
|
|
|
Mean change from Baseline in Estimated glomerular filtration rate (eGFR)
Time Frame: Baseline, Week 8, Week 12, Week 18, and Week 24
|
Baseline, Week 8, Week 12, Week 18, and Week 24
|
|
|
Number of participants who experience any treatment-related serious adverse event (SAE) or severe adverse events (AE) during the course of the treatment period or subsequent follow-up period
Time Frame: Throughout the study period of approximately 19 months
|
Throughout the study period of approximately 19 months
|
|
|
Number of participants who experience serious adverse events (SAEs) or adverse events (AEs)
Time Frame: Throughout the study period of approximately 19 months
|
Throughout the study period of approximately 19 months
|
|
|
Number of participants who experience temporally-related adverse events (AEs)
Time Frame: Baseline through 72 hours of IP administration
|
Temporally-related AEs - defined as AEs occurring during investigational product (IP) administration or within 72 hours of IP administration, regardless of causality
|
Baseline through 72 hours of IP administration
|
|
Number of participants with any clinically significant change in vital signs during investigational product (IP) administration or within 30 minutes following administration
Time Frame: Baseline through 30 minutes following IP administration
|
Baseline through 30 minutes following IP administration
|
|
|
Number of infusions associated with adverse events (AEs) or serious adverse events (SAEs) , regardless of causality
Time Frame: Throughout the study period of approximately 19 months
|
Throughout the study period of approximately 19 months
|
|
|
Number of infusions that had to be slowed, interrupted, or terminated due to adverse events (AEs) or serious adverse events (SAEs)
Time Frame: Throughout the study period of approximately 19 months
|
Throughout the study period of approximately 19 months
|
|
|
Number of participants with detectable levels of antidrug antibodies (ADAs)
Time Frame: Baseline, Week 3, Week 4, Week 12, Week 24, or early termination from the study
|
Baseline, Week 3, Week 4, Week 12, Week 24, or early termination from the study
|
|
|
Clinically significant abnormal laboratory assessments
Time Frame: Throughout the study period of approximately 19 months
|
Throughout the study period of approximately 19 months
|
|
|
Pharmacokinetics: maximum observed concentration (Cmax)
Time Frame: Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
|
|
Pharmacokinetics: time of maximum observed concentration (Cmax)
Time Frame: Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
|
|
Pharmacokinetics: area under the concentration-time curve during a dosing interval (AUC(0-tau))
Time Frame: Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
|
|
Pharmacokinetics: terminal half-life (t1/2)
Time Frame: Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
|
|
Pharmacokinetics: systemic clearance (CL)
Time Frame: Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
|
|
Pharmacokinetics: volume of distribution at the terminal phase (Vz)
Time Frame: Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
|
|
Pharmacokinetics: volume of distribution at steady state (Vss)
Time Frame: Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 181501
- 2015-002345-64 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.